Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V7FS-750 is a novel pH low insertion peptide (pHLIP) conjugated to the near-infrared fluorescent dye HiLyte 750. It is designed for the targeted imaging of the acidic microenvironment characteristic of solid tumors, specifically pancreatic cancer. The V7FS peptide is engineered to have an improved dynamic range compared to earlier pHLIPs like V3, with peak signal accumulation occurring at a pH of approximately 6.6. This allows for high-contrast imaging using multispectral optoacoustic imaging (MSOT) and near-infrared fluorescence (NIR). Developed by researchers at the OU Health Stephenson Cancer Center, V7FS-750 has demonstrated superior signal accumulation in orthotopic murine models of pancreatic cancer compared to previous iterations, facilitating more accurate tumor detection and intraoperative guidance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on V7FS-750.